EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR TKI, has shown objective response rates and progression-free survival compared with chemotherapy in the first-line setting and was recently approved as the first-line treatment for EGFR-mutated NSCLC (28).